Generalized Myasthenia Gravis
Conditions
Brief summary
Effective self administrations of zilucoplan using the zilucoplan-auto-injector (ZLP-AI) from Visit 1 to Visit 8.
Detailed description
- Effective self administration of zilucoplan using ZLP-AI at Visit 8 - Effective self administration of zilucoplan using ZLP-AI at Visit 1 - Occurrence of serious adverse events (SAEs) during the course of the study - Occurrence of treatment-emergent adverse events (TEAEs) during the course of the study - Occurrence of nonserious adverse device effects (ADE) during the course of the study - Occurrence of serious adverse device effects (SADE) during the course of the study
Interventions
Sponsors
UCB Biopharma
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective self administrations of zilucoplan using the zilucoplan-auto-injector (ZLP-AI) from Visit 1 to Visit 8. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Effective self administration of zilucoplan using ZLP-AI at Visit 8 - Effective self administration of zilucoplan using ZLP-AI at Visit 1 - Occurrence of serious adverse events (SAEs) during the course of the study - Occurrence of treatment-emergent adverse events (TEAEs) during the course of the study - Occurrence of nonserious adverse device effects (ADE) during the course of the study - Occurrence of serious adverse device effects (SADE) during the course of the study | — |
Countries
Poland
Outcome results
None listed